Centessa Pharmaceuticals PLC Form 4 insider transactions

Medicxi Ventures Management and affiliated entities report changes in beneficial ownership following the acquisition of Centessa Pharmaceuticals plc by Eli Lilly and Company.

Centessa Pharmaceuticals plc's acquisition by Eli Lilly and Company has been finalized, with shareholders set to receive cash and contingent value rights.

Centessa Pharmaceuticals plc's acquisition by Eli Lilly and Company has been finalized, with shareholders receiving cash and contingent value rights.

Centessa Pharmaceuticals plc's acquisition by Eli Lilly and Company has been finalized, with shareholders receiving cash and contingent value rights.

Centessa Pharmaceuticals plc's acquisition by Eli Lilly and Company is finalized, with shareholders receiving cash and contingent value rights.

Centessa Pharmaceuticals plc's acquisition by Eli Lilly and Company has been finalized, with shareholders receiving cash and contingent value rights.

Centessa Pharmaceuticals plc has been acquired by Eli Lilly and Company through a scheme of arrangement, with shareholders receiving cash and contingent value rights.

Centessa Pharmaceuticals plc's acquisition by Eli Lilly and Company has been finalized, with shareholders receiving cash and contingent value rights.

Centessa Pharmaceuticals plc's acquisition by Eli Lilly and Company has been finalized, with shareholders receiving cash and contingent value rights.

Francesco De Rubertis, a Director at Centessa Pharmaceuticals PLC, reported changes in beneficial ownership of ordinary shares on June 24, 2026, following the company's acquisition by Eli Lilly and Company.

Centessa Pharmaceuticals plc's acquisition by Eli Lilly and Company is finalized, with share options converted into cash and contingent value rights.

Arjun Goyal reports changes in beneficial ownership of Centessa Pharmaceuticals plc ordinary shares and options following an acquisition.

Centessa Pharmaceuticals CEO Mario Accardi reported the withholding of 604 ordinary shares to satisfy tax obligations related to RSU vesting.

Centessa Pharmaceuticals' Chief People Officer, Karen M. Anderson, exercised stock options and subsequently sold 41,076 ordinary shares for a significant gain.

Centessa Pharmaceuticals' Chief Business Officer, Gregory M Weinhoff, exercised options and sold 23,998 ordinary shares for $30 each.

Centessa Pharmaceuticals' Chief People Officer, Karen M. Anderson, exercised stock options and subsequently sold a portion of her ordinary shares in March 2026.

Centessa Pharmaceuticals' Chief People Officer, Karen M. Anderson, amended a Form 4 filing to correct details of stock option exercises and subsequent share sales under a pre-arranged trading plan.

Centessa Pharmaceuticals' Chief People Officer, Karen M. Anderson, exercised stock options and subsequently sold a substantial number of shares under a pre-arranged trading plan.

Centessa Pharmaceuticals' Chief Business Officer, Gregory M. Weinhoff, sold approximately $1.9 million worth of ordinary shares through a pre-arranged 10b5-1 trading plan.

Centessa Pharmaceuticals plc's Chief Medical Officer, Stephen Kanes, was granted 120,000 Restricted Share Units vesting over four years.

Centessa Pharmaceuticals plc's Chief Financial Officer, John J. Crowley, was granted 45,000 Restricted Share Units and options to purchase 181,000 Ordinary Shares, effective February 2, 2026.

Centessa Pharmaceuticals' Chief Accounting Officer, Raphael Deferiere, was granted 11,000 Restricted Share Units and options for 42,000 Ordinary Shares.

Centessa Pharmaceuticals' Chief Legal Officer, Iqbal J. Hussain, reported sales of ordinary shares while also receiving significant new restricted share units and stock options.

Centessa Pharmaceuticals' Chief Business Officer, Gregory M. Weinhoff, increased his beneficial ownership through new RSU and option grants, alongside a tax-related share disposition.

Centessa Pharmaceuticals CEO Mario Alberto Accardi reported the acquisition of 68,000 Restricted Share Units and 273,000 share options, alongside a tax-related disposition of 2,915 ordinary shares.

Centessa Pharmaceuticals' Chief People Officer, Karen M. Anderson, reported the vesting of restricted share units, a tax-related share disposition, and the grant of new share options.

Centessa Pharmaceuticals' Chief Technology & Quality Officer, Tia L. Bush, reported recent equity transactions including RSU grants and option awards.

Centessa Pharmaceuticals plc President of Orexin Program, Mario Alberto Accardi, sold a total of 10,000 ordinary shares on December 9, 2025, under a pre-arranged 10b5-1 trading plan.

Centessa Pharmaceuticals' President of Orexin Program, Mario Alberto Accardi, exercised stock options and subsequently sold a portion of his ordinary shares under a pre-arranged trading plan.

Centessa Pharmaceuticals' General Counsel, Iqbal J Hussain, exercised stock options and subsequently sold 6,000 ordinary shares under a pre-arranged trading plan.